- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
2024’s Biggest Weight Loss Drug Stories
GLP-1s continue to dominate the market, but can pharma keep up with the demand?
Stock.adobe.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Beyond GLP-1s: Q&A with Sandeep Makkar
The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care when treating obesity.
Counterfeit Weight Loss Drugs & Potential Health Risks
In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.
The Future of Obesity Pharmacology: Bridging Evidence Gaps with a New Model for Clinical Registries
The challenges in obesity research are significant, but the opportunities for innovation are equally profound.
Experts Weigh-In on Compounded GLP-1/Semaglutide Solution
Industry experts comment on the increasing popularity of compounded medications, particularly GLP-1s, due to drug shortages and the desire for personalized treatments.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
